Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review

Neuropsychiatric Disease and Treatment
Craig KarsonSteve J Offord

Abstract

Treatment during first-episode psychosis (FEP) or early schizophrenia may affect the rates of relapse and remission, as well as cognitive functioning, over time. Prolonged duration of psychosis is associated with a poor prognosis, but the effects of treatment in patients with FEP or early schizophrenia on the long-term outcomes are not well defined. To understand the long-term effects of treatment with antipsychotic agents on remission, relapse, and cognition in patients with FEP or early schizophrenia. Using PubMed and Scopus databases, a systematic review was undertaken of articles published between January 1, 2000, and May 20, 2015, that reported randomized and nonrandomized prospective clinical trials on the long-term effects of oral or long-acting injectable antipsychotics on measures of relapse, remission, or cognition in patients with FEP or early schizophrenia. For comparative purposes, trials reporting the effects of later intervention with antipsychotics in patients with longer disease history were also evaluated. Titles, abstracts, and full-text articles were independently screened for eligibility by all the authors based on the predefined criteria. Nineteen studies met inclusion criteria: 13 reported long-term outco...Continue Reading

Citations

Jun 18, 2017·Archives of Women's Mental Health·Kristopher A Kast, Smita Agarkar
Apr 25, 2018·International Journal of Clinical Practice·Jan Volavka, Jan Vevera
Nov 23, 2017·International Journal of Psychiatry in Clinical Practice·Eduard ParelladaUNKNOWN SHADOW Study Group
Dec 23, 2017·Journal of Nursing Measurement·Ana Carolina G ZanettiSueli Aparecida Frari Galera
Dec 13, 2018·International Clinical Psychopharmacology·Monika Salgueiro, Rafael Segarra
Aug 24, 2017·The Australian and New Zealand Journal of Psychiatry·Rosa-Elena UlloaRogelio Apiquian
May 30, 2019·Nordic Journal of Psychiatry·Renata AlisauskieneErik Johnsen
Feb 13, 2020·The American Journal of Psychiatry·Katherine G JonasRoman Kotov
Sep 26, 2017·Current Medical Research and Opinion·Kathleen BeusterienJohn F P Bridges
Aug 24, 2017·BMC Psychiatry·Rafal A H YeisenStein Opjordsmoen
Apr 23, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·D F KhritininE P Shchukina
Aug 25, 2016·Neurology and Therapy·Benedicto Crespo-FacorroJacqueline Mayoral-van Son
Sep 25, 2017·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Paolo Fusar-PoliJohn M Kane
Oct 24, 2020·Current Medical Research and Opinion·Benedicto Crespo-FacorroRichard Newton
Dec 22, 2020·Frontiers in Psychiatry·Maija LindgrenJaana Suvisaari
Mar 24, 2021·Early Intervention in Psychiatry·Martijn J KikkertIris E Sommer
Dec 8, 2021·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·D F ChritininV D Morozova
Dec 30, 2021·Nordic Journal of Psychiatry·Boris KarpovJaana Suvisaari

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA

Software Mentioned

Scopus

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Schizophrenia Research and Treatment
Eduard ParelladaWerner Kissling
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology
Brian J MillerKrystle Crittenden
© 2022 Meta ULC. All rights reserved